Skip to content
TrialScanner

NCT04404283

Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Phase 3Active, not recruitingPFELead

Registry record

Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Conditions
Diffuse Large B-cell Lymphoma
Primary completion
Jan 23, 2026Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT04404283 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT04404283: Brentuximab Vedotin Plus... | TrialScanner